Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior

被引:38
作者
Glick, ID
Zaninelli, R
Hsu, C
Young, FK
Weiss, L
Gunay, I
机构
[1] Novartis Pharmaceut Corp, Neurosci Clin Dev, E Hanover, NJ 07963 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
D O I
10.4088/jcp.v65n0513
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Results from the International Suicide Prevention Trial (InterSePT) indicate that clozapine is more effective than olanzapine in reducing suicidal behavior in schizophrenic and schizoaffective patients. However, because InterSePT allowed the uncontrolled use of concomitant psychotropic medications (CPMs), it is possible that the antisuicidal effect of clozapine may have been influenced by greater use of such agents. This article describes the use patterns of CPMs during InterSePT and examines whether CPM use may have affected study outcome. Method: In this study, 479 patients received clozapine and 477 patients received olanzapine. Concomitant psychotropic medications were grouped into 4 classes: antipsychotics, antidepressants, sedatives/anxiolytics, and mood stabilizers. The doses of each CPM were converted into dosage equivalents of standard reference drugs. An analysis of covariance was performed to compare mean daily doses of CPMs between the 2 groups over the 2-year treatment period. The duration of treatment for each patient was 2 years, with the first patient entering the study in March 1998 and the last patient completing treatment in February 2001. Results: Approximately 90% of patients in both treatment groups received at least 1 CPM. The mean +/- SD number of CPMs per patient was 3.8 +/- 2.90 in the clozapine group and 4.2 +/- 3.16 in the olanzapine group. For each CPM class, the mean daily dose was statistically significantly lower in the clozapine group (antipsychotics, p < .001; antidepressants, p < .01; sedatives/anxiolytics, p < .001; mood stabilizers, p < .05). Analyses of CPM use by study intervals, suicide attempters versus nonattempters, study completers versus noncompleters, and geographic region resulted in similar findings. Conclusion: The results support the conclusion that the effects of clozapine in reducing the risk of suicidal behavior derive from its intrinsic pharmacology and not from the influence of concomitant psychotropic medications.
引用
收藏
页码:679 / 685
页数:7
相关论文
共 11 条
[1]  
BEZCHLIBNYKBUTL.KZ, 2002, CLIN HDB PSYCHOTROPI, P1
[2]  
BROTMAN AW, 1990, J CLIN PSYCHIAT, V51, P164
[3]   The long-term outcome of a benzodiazepine discontinuation programme in depressed outpatients [J].
Couvée, JE ;
Timmermans, MAY ;
Zitman, FG .
JOURNAL OF AFFECTIVE DISORDERS, 2002, 70 (02) :133-141
[4]   Antipschotic medication coprescribing in a large state hospital system [J].
Jaffe, AB ;
Levine, J .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (01) :41-48
[5]   Clozapine treatment for suicidality in schizophrenia - International Suicide Prevention Trial (InterSePT) [J].
Meltzer, HY ;
Alphs, L ;
Green, AI ;
Altamura, AC ;
Anand, R ;
Bertoldi, A ;
Bourgeois, M ;
Chouinard, G ;
Islam, Z ;
Kane, J ;
Krishnan, R ;
Lindenmayer, JP ;
Potkin, S .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (01) :82-91
[6]   Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics [J].
Rittmannsberger, H ;
Meise, U ;
Schauflinger, K ;
Horvath, E ;
Donat, H ;
Hinterhuber, H .
EUROPEAN PSYCHIATRY, 1999, 14 (01) :33-40
[7]   National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) - Alzheimer disease trial methodology [J].
Schneider, LS ;
Tariot, PN ;
Lyketsos, CG ;
Dagerman, KS ;
Davis, KL ;
Davis, S ;
Hsiao, JK ;
Jeste, DV ;
Katz, IR ;
Olin, JT ;
Pollock, BG ;
Rabins, PV ;
Rosenheck, RA ;
Small, GW ;
Lebowitz, B ;
Lieberman, JA .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2001, 9 (04) :346-360
[8]   ADJUNCTIVE MEDICATION IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA AND ITS CONCEPTUAL IMPLICATIONS [J].
SIRIS, SG .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :66-78
[9]   Combination antipsychotic therapy in clinical practice [J].
Tapp, A ;
Wood, AE ;
Secrest, L ;
Erdmann, J ;
Cubberley, L ;
Kilzieh, N .
PSYCHIATRIC SERVICES, 2003, 54 (01) :55-59
[10]  
*WHO COLL CTR DRUG, 2002, AN THER CHEM ATC IND